Malek Faham
Amministratore Delegato presso Serimmune, Inc.
Posizioni attive di Malek Faham
Società | Posizione | Inizio | Fine |
---|---|---|---|
IIF Management Co. LLC
IIF Management Co. LLC Investment ManagersFinance IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California. | Direttore Tecnico/Scientifico/R&S | 24/05/2022 | - |
Investitore di Private Equity | 31/10/2017 | 24/05/2022 | |
AccuraGen, Inc.
AccuraGen, Inc. BiotechnologyHealth Technology AccuraGen, Inc. engages in cancer diagnostic and research. It develops sequencing-based cancer-mutation detection systems. The company was founded by Shengrong Lin, Kang Ying, Johnny Sun, Paul Tang and Grace Zhao in 2013 and is headquartered in Menlo Park, CA. | Direttore Tecnico/Scientifico/R&S | 01/06/2015 | - |
Serimmune, Inc.
Serimmune, Inc. Pharmaceuticals: MajorHealth Technology Serimmune, Inc. develops diagnostics and therapeutics for autoimmune diseases. Its Immune IT platform provides composition of functional immune repertoires, creating new opportunities for therapeutic and diagnostic development. The company was founded by Patrick S. Daugherty and is headquartered in Goleta, CA. | Direttore/Membro del Consiglio | - | - |
Amministratore Delegato | - | - | |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Malek Faham
Precedenti posizioni note di Malek Faham
Società | Posizione | Inizio | Fine |
---|---|---|---|
Convergent Genomics, Inc.
Convergent Genomics, Inc. BiotechnologyHealth Technology Convergent Genomics, Inc. operates as genomic liquid biopsy company leveraging cutting-edge data analytics to transform cancer care The company was founded by Trevor Levin and is headquartered in San Francisco, CA. | Consulente / Consigliere | 01/10/2015 | 01/12/2019 |
AFFYMETRIX, INC. | Corporate Officer/Principal | 01/01/2008 | 01/01/2008 |
ParAllele BioScience, Inc.
ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Direttore Tecnico/Scientifico/R&S | 01/01/2005 | 01/01/2005 |
Fondatore | 01/01/2005 | 01/01/2005 | |
Vineti, Inc.
Vineti, Inc. Medical/Nursing ServicesHealth Services Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA. | Direttore Tecnico/Scientifico/R&S | - | - |
Fondatore | - | - | |
Stanford Genome Technology Center | Corporate Officer/Principal | - | - |
░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Malek Faham
University of Maryland | Undergraduate Degree |
The University of California, San Francisco | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 13 |
Posizioni
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 3 |
Founder | 3 |
Settori
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 10 |
---|---|
Affymetrix, Inc.
Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
ParAllele BioScience, Inc.
ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Commercial Services |
Sequenta, Inc.
Sequenta, Inc. BiotechnologyHealth Technology Sequenta, Inc. operates as a biotech company which discovers and develops clinical diagnostics based on immune system status. It develops molecular diagnostic assays based on a sequencing approach to the profiling of T and B cell receptor repertoires. The firm also provides sequencing-based test for minimal residual disease for leukemia and lymphoma. The company was founded by Thomas D. Willis and Malek Faham in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
Stanford Genome Technology Center | |
AccuraGen, Inc.
AccuraGen, Inc. BiotechnologyHealth Technology AccuraGen, Inc. engages in cancer diagnostic and research. It develops sequencing-based cancer-mutation detection systems. The company was founded by Shengrong Lin, Kang Ying, Johnny Sun, Paul Tang and Grace Zhao in 2013 and is headquartered in Menlo Park, CA. | Health Technology |
Vineti, Inc.
Vineti, Inc. Medical/Nursing ServicesHealth Services Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA. | Health Services |
IIF Management Co. LLC
IIF Management Co. LLC Investment ManagersFinance IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California. | Finance |
Serimmune, Inc.
Serimmune, Inc. Pharmaceuticals: MajorHealth Technology Serimmune, Inc. develops diagnostics and therapeutics for autoimmune diseases. Its Immune IT platform provides composition of functional immune repertoires, creating new opportunities for therapeutic and diagnostic development. The company was founded by Patrick S. Daugherty and is headquartered in Goleta, CA. | Health Technology |
Convergent Genomics, Inc.
Convergent Genomics, Inc. BiotechnologyHealth Technology Convergent Genomics, Inc. operates as genomic liquid biopsy company leveraging cutting-edge data analytics to transform cancer care The company was founded by Trevor Levin and is headquartered in San Francisco, CA. | Health Technology |
Protillion Biosciences, Inc.
Protillion Biosciences, Inc. BiotechnologyHealth Technology Protillion Biosciences, Inc. is a company based in Burlingame, CA that was founded in 2019 by Will Greenleaf, David R. Walt, and Curtis Layton. The company specializes in commercializing disruptive technology for therapeutic antibody and binder discovery. The company's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run, enabling the identification of better antibody candidates on an exponentially faster timeline compared to current state-of-the-art antibody discovery and optimization techniques that may take months of laborious laboratory procedures executed by highly-skilled practitioners. Curtis Layton has been the CEO since 2019. | Health Technology |
- Borsa valori
- Insiders
- Malek Faham
- Esperienza